Capricor Therapeutics (NASDAQ:CAPR) Trading 12.2% Higher – Here’s What Happened

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) traded up 12.2% during trading on Wednesday . The company traded as high as $25.58 and last traded at $25.8510. 921,906 shares changed hands during trading, a decline of 23% from the average session volume of 1,196,288 shares. The stock had previously closed at $23.03.

Wall Street Analysts Forecast Growth

CAPR has been the topic of a number of research analyst reports. Maxim Group lifted their target price on Capricor Therapeutics from $25.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Capricor Therapeutics in a research note on Monday, December 29th. Oppenheimer boosted their target price on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Piper Sandler reissued an “overweight” rating and issued a $45.00 price objective (up previously from $20.00) on shares of Capricor Therapeutics in a research report on Wednesday, December 10th. Finally, Alliance Global Partners restated a “buy” rating on shares of Capricor Therapeutics in a report on Wednesday, December 3rd. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $40.82.

Capricor Therapeutics Stock Up 10.7%

The business’s 50 day moving average price is $25.49 and its 200-day moving average price is $13.98. The company has a market cap of $1.17 billion, a PE ratio of -14.16 and a beta of 0.38.

Institutional Trading of Capricor Therapeutics

Several large investors have recently modified their holdings of the business. Suvretta Capital Management LLC purchased a new position in Capricor Therapeutics in the fourth quarter valued at about $51,533,000. Tang Capital Management LLC purchased a new position in shares of Capricor Therapeutics during the 4th quarter valued at approximately $49,062,000. RA Capital Management L.P. acquired a new stake in shares of Capricor Therapeutics during the fourth quarter worth approximately $43,516,000. Darwin Global Management Ltd. bought a new stake in shares of Capricor Therapeutics in the fourth quarter worth $23,168,000. Finally, Vanguard Group Inc. raised its holdings in Capricor Therapeutics by 16.1% in the fourth quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock valued at $73,936,000 after acquiring an additional 355,161 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.